Zacks Investment Research cut shares of Emergent Biosolutions (NYSE:EBS) from a hold rating to a sell rating in a research report released on Friday morning.

According to Zacks, “Emergent derives the majority of revenues from sales of BioThrax. Hence, it’s sole dependence on BioThrax for its revenues is concerning. Any hiccup in the production of BioThrax could severely hamper the company’s future growth prospects. Moreover, Emergent depends on certain single-source suppliers for key materials and services that are necessary for the manufacture of BioThrax which is also a matter of concern. Meanwhile, Emergent faces competition from a number of companies with Biodefense products. However, the company’s follow-on contract with the CDC and deals with the BARDA for BioThrax and NuThrax (next-generation anthrax vaccine) bode well for growth. We are also positive on Emergent’s spin-off of its biosciences business into a separate publicly traded company as it resulted in reduction of the company’s cost structure. Shares of the company have outperformed the broader industry in the last one year.”

A number of other research analysts have also weighed in on EBS. Goldman Sachs Group began coverage on shares of Emergent Biosolutions in a research note on Wednesday, January 24th. They issued a neutral rating and a $55.00 price objective on the stock. Chardan Capital raised their price objective on shares of Emergent Biosolutions from $47.00 to $53.00 and gave the company a buy rating in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Emergent Biosolutions currently has a consensus rating of Hold and a consensus price target of $51.00.

Emergent Biosolutions (EBS) traded down $0.58 during trading on Friday, hitting $44.44. 733,653 shares of the company’s stock were exchanged, compared to its average volume of 324,052. Emergent Biosolutions has a 12-month low of $27.94 and a 12-month high of $51.25. The company has a market capitalization of $2,170.00, a price-to-earnings ratio of 27.78, a price-to-earnings-growth ratio of 0.93 and a beta of 1.32. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.37 and a quick ratio of 6.46.

In other news, Director Zsolt Harsanyi sold 7,000 shares of the stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $42.47, for a total value of $297,290.00. Following the completion of the sale, the director now owns 37,077 shares in the company, valued at $1,574,660.19. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Chairman Fuad El-Hibri sold 47,983 shares of the stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $41.88, for a total transaction of $2,009,528.04. Following the completion of the sale, the chairman now owns 1,550,216 shares of the company’s stock, valued at approximately $64,923,046.08. The disclosure for this sale can be found here. Insiders sold 165,722 shares of company stock worth $7,219,341 over the last ninety days. Insiders own 16.50% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Northern Trust Corp increased its holdings in Emergent Biosolutions by 47.2% during the second quarter. Northern Trust Corp now owns 906,731 shares of the biopharmaceutical company’s stock worth $30,747,000 after buying an additional 290,863 shares during the last quarter. Peregrine Capital Management LLC increased its holdings in Emergent Biosolutions by 40.8% during the third quarter. Peregrine Capital Management LLC now owns 454,857 shares of the biopharmaceutical company’s stock worth $18,399,000 after buying an additional 131,692 shares during the last quarter. Rice Hall James & Associates LLC increased its holdings in Emergent Biosolutions by 19.6% during the fourth quarter. Rice Hall James & Associates LLC now owns 769,096 shares of the biopharmaceutical company’s stock worth $35,740,000 after buying an additional 126,069 shares during the last quarter. Boston Advisors LLC increased its holdings in Emergent Biosolutions by 814.8% during the fourth quarter. Boston Advisors LLC now owns 132,332 shares of the biopharmaceutical company’s stock worth $6,149,000 after buying an additional 117,867 shares during the last quarter. Finally, New Amsterdam Partners LLC NY increased its holdings in Emergent Biosolutions by 60.0% during the fourth quarter. New Amsterdam Partners LLC NY now owns 261,371 shares of the biopharmaceutical company’s stock worth $12,146,000 after buying an additional 98,034 shares during the last quarter. Institutional investors own 74.31% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Downgrades Emergent Biosolutions (EBS) to Sell” was first published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.dailypolitical.com/2018/02/10/zacks-investment-research-downgrades-emergent-biosolutions-ebs-to-sell.html.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Get a free copy of the Zacks research report on Emergent Biosolutions (EBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.